title: [Two cases of CPT-11 and CDDP chemotherapy for advanced pancreatic cancer].
abstract: We report two cases of advanced pancreatic cancer treated with CPT-11 and CDDP as third-line chemotherapy. CPT-11 was administered as an intravenous injection at a dose of 60 mg/m², and CDDP was administered at a dose of 30 mg/m2 biweekly. The patients showed no adverse events greater than grade 2 toxicity, and these adverse events were tolerated. The patients showed partial response and stable disease. These results suggested that this treatment schedule was safe and effective for progressive pancreatic cancer.
authors.affiliation: Department of Surgery, Kurashiki Central Hospital.
authors.forename: Kosei
authors.initials: K
authors.lastname: Takagi
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Kawamoto
authors.forename: Tadashi
authors.initials: T
authors.lastname: Itoh
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014057:Tomography, X-Ray Computed
chemical_list: D000077146:Irinotecan; D002945:Cisplatin; D002166:Camptothecin